Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Symbicort Turbuhaler 160/4.5 microg/Inhalation, Two Inhalations Twice Daily Plus as-Needed Compared With Seretide Diskus 50/500 microg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation as-Needed - a 6-Month, Randomised, Double-Blind, Parallel-Group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD)

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Symbicort Turbuhaler 160/4.5 microg/Inhalation, Two Inhalations Twice Daily Plus as-Needed Compared With Seretide Diskus 50/500 microg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation as-Needed - a 6-Month, Randomised, Double-Blind, Parallel-Group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate; Terbutaline
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms AHEAD
  • Sponsors AstraZeneca

    • Most Recent Events

    • 19 Nov 2020 Results of economic analysis from three clinical trials: COMPASS, COSMOS and AHEAD presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 01 Jan 2018 Results of pooled post-hoc analysis from six studies (STEAM, STEP, STAY, SMILE, COMPASS and AHEAD) published in the European Respiratory Journal.
    • 22 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top